Loading...
XSHG
603367
Market cap1.17bUSD
Dec 05, Last price  
18.33CNY
1D
0.83%
1Q
-27.29%
IPO
-0.76%
Name

Cisen Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603367 chart
P/E
16.31
P/S
2.08
EPS
1.12
Div Yield, %
2.38%
Shrs. gr., 5y
0.05%
Rev. gr., 5y
-0.65%
Revenues
3.98b
-10.77%
1,531,420,9852,051,722,0582,205,981,8812,388,354,5642,496,971,9892,564,801,1062,962,516,5253,808,078,4264,112,785,5103,674,158,4753,782,592,6354,066,088,4484,462,348,6363,981,572,232
Net income
509m
-2.38%
236,929,557283,857,304208,298,936220,152,035246,854,932246,881,899367,221,928503,544,862514,580,078438,784,463334,146,422349,958,583521,338,330508,906,193
CFO
571m
+26.51%
033,086,38281,260,05527,538,117266,243,874291,972,115439,607,583406,675,789181,263,844431,007,158233,598,087258,345,605451,240,761570,848,680
Dividend
Jun 27, 20240.436 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells chemical drug preparations and health care products in China and internationally. The company's chemical drug preparations include liver disease drugs, antitumor and auxiliary drugs, nutrition preparations, contrast agents, antibiotics, digestive system agents, polypropylene ampoules, and external preparations, as well as sedation anesthesia, cardiovascular, cough and asthma, immunomodulator, infusion, and therapeutic infusion products. The company was formerly known as Shandong Lukang Cisen Pharmaceutical Co., Ltd. and changed its name to Cisen Pharmaceutical Co., Ltd. in 2011. Cisen Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Jining, the People's Republic of China.
URL
http://www.cisen-pharma.com/
IPO date
Sep 29, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT